Earnings summaries and quarterly performance for Trevi Therapeutics.
Executive leadership at Trevi Therapeutics.
Board of directors at Trevi Therapeutics.
Research analysts who have asked questions during Trevi Therapeutics earnings calls.
Faisal Khurshid
Leerink Partners
4 questions for TRVI
Also covers: ABCL, ANIP, GERN +4 more
Annabel Samimy
Stifel Financial Corp.
3 questions for TRVI
Also covers: ALT, APLS, CARA +14 more
BF
Brandon Folkes
Rodman & Renshaw
3 questions for TRVI
Also covers: ACHV, ANIP, AVDL +10 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
3 questions for TRVI
Also covers: ABSI, CLSD, EYPT +2 more
KP
Kaveri Pohlman
BTIG, LLC
3 questions for TRVI
Also covers: MDGL, MGNX, NUVB +3 more
LG
Leland Gershell
Oppenheimer & Co. Inc.
3 questions for TRVI
Also covers: ARGX, ASND, CAPR +13 more
Mayank Mamtani
B. Riley Securities
3 questions for TRVI
Also covers: AGEN, ALT, ARWR +18 more
Ryan Deschner
Raymond James Financial
3 questions for TRVI
Also covers: APLS, ARDX, ARSP +7 more
SB
Serge Belanger
Needham & Company
2 questions for TRVI
Also covers: AMPH, ARQT, BCRX +12 more
AD
Alexa Deemer
Cantor Fitzgerald
1 question for TRVI
Also covers: IVVD, SPRY
Anthony
Raymond James
1 question for TRVI
Also covers: AB, COO, WVE
JD
Jason Dorr
Oppenheimer & Co. Inc.
1 question for TRVI
Also covers: XERS
JG
John Gionco
Needham & Co.
1 question for TRVI
Also covers: AMPH, CYTK, PCRX
WW
William Wood
B. Riley Securities
1 question for TRVI
Also covers: ALT, GUTS, IMUX +3 more
Recent press releases and 8-K filings for TRVI.
Tvardi Therapeutics Under Investigation by Faruqi & Faruqi
TRVI
Legal Proceedings
Demand Weakening
Profit Warning
- Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
- The investigation follows a plummet of over 80% in Tvardi's shares on Monday, October 13, 2025, after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101.
- The Phase 2 REVERT study, which assessed safety, pharmacokinetics, and exploratory outcomes related to lung function for TTI-101 in idiopathic pulmonary fibrosis, did not meet its goals after reviewing preliminary safety and exploratory efficacy results, including changes in Forced Vital Capacity (FVC).
Dec 24, 2025, 4:23 PM
Tvardi Therapeutics Shares Plummet After Failed Clinical Trial Data, Leading to Legal Investigation
TRVI
Legal Proceedings
New Projects/Investments
- Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD) on behalf of investors who suffered significant losses.
- This investigation follows a more than 80% plummet in Tvardi's shares on Monday, October 13, 2025, due to disappointing preliminary data from its Phase 2 REVERT clinical trial.
- The company concluded that the Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis did not meet its goals after reviewing preliminary safety and exploratory efficacy results, including changes in Forced Vital Capacity (FVC).
Dec 20, 2025, 1:01 PM
Tvardi Therapeutics under investigation by Faruqi & Faruqi
TRVI
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. (TRVI).
- The investigation follows a more than 80% plummet in Tvardi's shares on October 13, 2025.
- This significant stock decline was triggered by disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis, which the company concluded did not meet its goals.
Dec 10, 2025, 2:52 PM
Faruqi & Faruqi Investigates Tvardi Therapeutics Following Stock Plunge
TRVI
Legal Proceedings
Demand Weakening
- Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
- This investigation follows a significant stock plummet of over 80% on October 13, 2025.
- The stock drop was caused by disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis, which did not meet its goals regarding safety and exploratory efficacy results.
- Investors who suffered significant losses in Tvardi stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights.
Dec 3, 2025, 2:50 PM
Trevi Therapeutics Reports Q3 2025 Financial Results and Clinical Program Updates
TRVI
Earnings
Guidance Update
New Projects/Investments
- Trevi Therapeutics reported a net loss of $11.8 million for the third quarter of 2025, with R&D expenses decreasing to $10.1 million and G&A expenses increasing to $3.8 million compared to the same quarter last year.
- As of September 30, 2025, the company held approximately $195 million in cash and investments, providing a cash runway into 2028. This follows a $115 million capital raise in June.
- The company plans to request an end of phase two meeting with the FDA in Q4 2025 for its IPF cough program and aims to initiate phase three studies in the first half of 2026.
- Recent phase one studies for the IPF cough program, including a drug-drug interaction study and a respiratory function and safety study (Tidal), have shown no clinically meaningful changes or safety signals.
- Trevi also plans to initiate a phase 2b parallel arm dose-ranging study for refractory chronic cough and a study for non-IPF interstitial lung diseases in the first half of 2026.
Nov 13, 2025, 9:30 PM
Trevi Therapeutics Reports Q3 2025 Financial Results and Provides Clinical Development Update
TRVI
Earnings
Guidance Update
New Projects/Investments
- Trevi Therapeutics reported a net loss of $11.8 million for the third quarter of 2025, an improvement compared to a net loss of $13.2 million for the same quarter in 2024.
- As of September 30, 2025, the company's cash and investments totaled approximately $195 million, providing a cash runway into 2028.
- The company plans to request an end of phase two meeting with the FDA in the fourth quarter of 2025 to discuss the phase three program for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
- Trevi Therapeutics is preparing to initiate multiple clinical trials in the first half of next year, including the phase three program for IPF, a study in non-IPF interstitial lung diseases (ILD), and a phase 2b study for refractory chronic cough (RCC).
Nov 13, 2025, 9:30 PM
Trevi Therapeutics Reports Q3 2025 Financials and Provides Clinical Development Updates
TRVI
Earnings
Guidance Update
New Projects/Investments
- Trevi Therapeutics reported a net loss of $11.8 million for Q3 2025, an improvement from a net loss of $13.2 million in Q3 2024.
- The company's cash and investments totaled approximately $195 million as of September 30, 2025, providing a cash runway into 2028.
- Key clinical progress includes positive results from a drug-drug interaction study and a respiratory safety study (TIDAL sentinel cohort) for nalbuphine ER, showing no clinically meaningful changes or safety signals.
- Trevi plans to request an End of Phase II meeting with the FDA in Q4 2025 for its IPF cough program and intends to initiate Phase III trials for IPF cough, a study for non-IPF ILD, and a Phase IIb study for refractory chronic cough in H1 2026.
Nov 13, 2025, 9:30 PM
Trevi Therapeutics Reports Q3 2025 Financial Results and Provides Business Updates
TRVI
Earnings
Guidance Update
New Projects/Investments
- Trevi Therapeutics reported a net loss of $11.8 million for the third quarter of 2025.
- The company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2028.
- Trevi is preparing to initiate a comprehensive Phase 3 program for chronic cough in IPF in the first half of 2026 and plans to submit its End-of-Phase 2 meeting request to the FDA in Q4 2025.
- Research and development expenses for Q3 2025 decreased to $10.1 million from $11.2 million in the same period in 2024.
Nov 13, 2025, 9:08 PM
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
TRVI
Earnings
New Projects/Investments
Guidance Update
- Trevi Therapeutics ended the third quarter of 2025 with $194.9 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2028.
- The company plans to submit its End-of-Phase 2 meeting request to the FDA in the fourth quarter of 2025 and initiate its Phase 3 program for chronic cough in idiopathic pulmonary fibrosis in the first half of 2026.
- For the third quarter of 2025, the company reported a net loss of $11.8 million.
Nov 13, 2025, 9:05 PM
Faruqi & Faruqi, LLP Investigates Tvardi Therapeutics Following Clinical Trial Disappointment
TRVI
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
- This investigation follows a more than 80% plummet in Tvardi's shares on October 13, 2025, after preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis did not meet its goals.
- The company concluded that the study did not meet its objectives after reviewing preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC).
Nov 9, 2025, 2:18 PM
Quarterly earnings call transcripts for Trevi Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more